OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
Andrea Ossato, Vera Damuzzo, Paolo Baldo, et al.
Cancer Medicine (2022) Vol. 12, Iss. 3, pp. 2155-2165
Open Access | Times Cited: 12
Andrea Ossato, Vera Damuzzo, Paolo Baldo, et al.
Cancer Medicine (2022) Vol. 12, Iss. 3, pp. 2155-2165
Open Access | Times Cited: 12
Showing 12 citing articles:
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
Andrea Messori, Vera Damuzzo, Melania Rivano, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1633-1633
Open Access | Times Cited: 22
Andrea Messori, Vera Damuzzo, Melania Rivano, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1633-1633
Open Access | Times Cited: 22
A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Andrea Messori, Sabrina Trippoli, Eugenia Piragine, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 503-503
Open Access
Andrea Messori, Sabrina Trippoli, Eugenia Piragine, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 503-503
Open Access
Applications of mRNA Delivery in Cancer Immunotherapy
Xiaoyu Pan, Yang-Wen-Qing Zhang, Caixia Dai, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 3339-3361
Open Access
Xiaoyu Pan, Yang-Wen-Qing Zhang, Caixia Dai, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 3339-3361
Open Access
Relatlimab–nivolumab: A practical overview for dermatologists
Nikita Mullick, Vinod E. Nambudiri
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 5, pp. 1031-1037
Closed Access | Times Cited: 8
Nikita Mullick, Vinod E. Nambudiri
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 5, pp. 1031-1037
Closed Access | Times Cited: 8
The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data
Shuang Zhang, Shuang Li, Ying Cheng
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Shuang Zhang, Shuang Li, Ying Cheng
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Long‐term progression‐free survival in patients with chronic lymphocytic leukemia treated with novel agents: An analysis based on indirect comparisons
Andrea Messori
European Journal Of Haematology (2022) Vol. 110, Iss. 1, pp. 60-66
Closed Access | Times Cited: 7
Andrea Messori
European Journal Of Haematology (2022) Vol. 110, Iss. 1, pp. 60-66
Closed Access | Times Cited: 7
Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma
Márton Tompa, Zoltán Krabóth, Bence Gálik, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2174-2174
Open Access | Times Cited: 6
Márton Tompa, Zoltán Krabóth, Bence Gálik, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2174-2174
Open Access | Times Cited: 6
The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
Paolo A. Ascierto, Christian U. Blank, Alexander M.M. Eggermont, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Paolo A. Ascierto, Christian U. Blank, Alexander M.M. Eggermont, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 3
The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
Andrea Messori, Melania Rivano, Luca Cancanelli, et al.
Cureus (2022)
Open Access | Times Cited: 4
Andrea Messori, Melania Rivano, Luca Cancanelli, et al.
Cureus (2022)
Open Access | Times Cited: 4
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
Andrea Messori, Melania Rivano, Daniele Mengato, et al.
Cureus (2022)
Open Access | Times Cited: 3
Andrea Messori, Melania Rivano, Daniele Mengato, et al.
Cureus (2022)
Open Access | Times Cited: 3
Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma
Meng Li, Kaiping Liao, Małgorzata Nowakowska, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 11, pp. 1232-1241
Open Access | Times Cited: 1
Meng Li, Kaiping Liao, Małgorzata Nowakowska, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 11, pp. 1232-1241
Open Access | Times Cited: 1
Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials
Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, et al.
World Journal of Urology (2022) Vol. 40, Iss. 11, pp. 2609-2615
Closed Access | Times Cited: 1
Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, et al.
World Journal of Urology (2022) Vol. 40, Iss. 11, pp. 2609-2615
Closed Access | Times Cited: 1
